Amphastar Pharmaceuticals, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $719.9M | $732.0M | $644.4M | $499.0M | $437.8M |
| Gross profit | $356.1M | $373.9M | $351.1M | $248.9M | $199.7M |
| Operating income | $140.4M | $205.4M | $197.0M | $107.5M | $69.9M |
| Operating expenses | $215.7M | $168.4M | $154.1M | $141.4M | $129.9M |
| Cost of revenue | $363.8M | $358.1M | $293.3M | $250.1M | $238.0M |
| Cash from operations | $156.1M | $213.4M | $183.5M | $89.2M | $98.0M |
| Capital expenditure | $34.9M | $41.0M | $38.2M | $24.0M | $27.5M |
| Free cash flow | $121.2M | $172.3M | $145.3M | $65.1M | $70.5M |
| Share repurchases | $75.6M | $85.5M | $58.1M | $39.9M | $28.9M |
| Total assets | $1.6B | $1.6B | $1.5B | $742.0M | $671.5M |
| Total liabilities | $840.5M | $845.2M | $873.5M | $213.3M | $226.0M |
Shares outstanding 44.1M · Free float 75.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.